Over 100 Total Lots Up For Auction at One Location - CA 12/04

Byotrol Keeps Hospital Super Bug Free for Two Years

by Lynn Shapiro, Writer | October 28, 2008
An innovative antimicrobial
is safe on medical equipment
MRSA and other super bugs may be the single biggest challenge facing hospitals and out-patient centers today, but now a product--Byotrol--developed by a British company, also called Byotrol, has helped create a hospital in the U.S. that is free of hospital acquired MRSA, VRE and C.difficile.

Since the Monroe Hospital opened in Bloomington Indiana, in October 2006, there has never been a recorded case of hospital acquired MRSA, C.difficile or the VRE super bug. VRE is becoming a major issue for the North American healthcare system, the company says. Stephen Falder, deputy chairman of Byotrol is the inventor of the product.

"And this breakthrough British technology offers a real solution to the super bug crisis currently gripping UK hospitals according to one of the UK's foremost experts in hospital acquired infection," Falder says.
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

Monroe Hospital's Director of Infection Prevention, James Ballard, puts much of this remarkable success story down to the technology provided by Byotrol, whose anti-microbial technology has helped keep super bugs at bay across the hospital.

The hospital treats around 13,000 patients every year and would ordinarily be at high risk of hospital acquired infection because it undertakes around 3,000 bone and joint surgical procedures including hip replacements every year, with many of these being undertaken on older patients. Yet despite this, there has never been an outbreak of hospital acquired infection thanks to the Byotrol technology, the company writes in a press release.

Byotrol has revealed that a study into Byotrol technology at a leading teaching hospital in the North West of England has shown extremely promising initial results.

Preliminary results including 12 weeks of data are planned to be published in early December. The early results are extremely encouraging when compared to chlorine based cleaning. One of the biggest challenges facing the National Health System at the moment is to find a technology that offers the biocidal performance of chlorine based products without the damage to equipment and fabric associated with using such products. If the results from this study continue to follow the trends shown to date, Byotrol could well be the answer to this challenge.

Byotrol is an anti-microbial technology which is unlike anything else on the market because it continues to kill micro-organisms for days after it has been applied and even after it has dried (called residual efficacy).

In comparison, a disinfectant such as bleach is only effective for a maximum of a couple of minutes after it has been applied. After that micro-organisms start to recolonize on a surface.

The technology kills resistant and difficult to kill organisms such as MRSA and VRE yet despite its success at killing super bugs, it is extremely gentle on human skin compared to other disinfectants used in hospitals and requires no special precautions or equipment to use it.